Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nutriband Inc WT (NQ: NTRBW ) 0.9800 +0.0100 (+1.03%) Streaming Delayed Price Updated: 1:24 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nutriband Inc WT < Previous 1 2 3 4 Next > Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 September 04, 2024 Via ACCESSWIRE Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25 July 19, 2024 Via ACCESSWIRE Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology July 15, 2024 Via ACCESSWIRE Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl June 20, 2024 Via ACCESSWIRE Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year June 03, 2024 Via ACCESSWIRE Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors May 16, 2024 Via ACCESSWIRE Nutriband Inc. Announces $8.4M Private Placement April 19, 2024 Via ACCESSWIRE Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st January 29, 2024 Via ACCESSWIRE Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission April 24, 2024 Via ACCESSWIRE Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group April 23, 2024 Via ACCESSWIRE Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance April 01, 2024 Via ACCESSWIRE Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch March 27, 2024 Via ACCESSWIRE Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting March 25, 2024 Via ACCESSWIRE Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology September 20, 2023 Via ACCESSWIRE Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023 September 12, 2023 Via ACCESSWIRE Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador August 30, 2023 Via ACCESSWIRE Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission July 14, 2023 Via ACCESSWIRE Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting March 04, 2024 Via ACCESSWIRE Nutriband CEO Publishes Letter to Shareholders January 26, 2024 Via ACCESSWIRE Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch January 05, 2024 Via ACCESSWIRE Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling November 28, 2023 Via ACCESSWIRE Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape November 08, 2023 Via ACCESSWIRE Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm October 11, 2023 Via ACCESSWIRE Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications September 20, 2023 Via Get News Topics Intellectual Property Exposures Intellectual Property Nutriband Unveils Groundbreaking Innovation in Transdermal Medications September 20, 2023 ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance... Via TheNewswire.com Topics Intellectual Property Exposures Intellectual Property Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology September 20, 2023 Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of... Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise September 20, 2023 EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Intellectual Property Exposures Death Intellectual Property Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update September 11, 2023 Via ACCESSWIRE Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings July 27, 2023 ORLANDO, FL / PlatoData via 500NewsWire / July 27, 2023 / Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of... Via TheNewswire.com Topics Artificial Intelligence Exposures Artificial Intelligence Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings July 27, 2023 Via ACCESSWIRE < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.